Biosimilar medicines: an opportunity for healthcare
Since 2006, biosimilar medicines have generated more than 400 Million patient days of clinical experience. Healthcare professionals and patients can be confident that authorised biosimilar medicines have been demonstrated to be of high quality and as safe and efficacious as their reference product. So what are biosimilar medicines?
Generic, Biosimilar and Value Added Medicines central to equitable Access to Healtchare
Riga, 30 June 2015 - At the Universal Health Conference celebrated in Riga during the last two days, the EGA (European Generic and Biosimilar medicines Association) joined forces with the Latvian EU Presidency and stakeholders EFPIA (European Federation of Pharmaceutical Industries and Associations), EPF (European Patients Forum) and EPHA (European Public Health Alliance) to address universal health and wellbeing in Europe.
The European Medicines Verification Organisation (EMVO) signs framework agreements with service providers to establish blueprint systems
22 June 2015 - Brussels - The stakeholder organisation EMVO has finalised last Friday its contract negotiations with 3 partners that will be the preferred providers to implement the repositories system in compliance with the Falsified Medicines Directive.
New IMS Report highlights the importance of Generic medicines in sustaining European healthcare systems
Brussels, 16 June 2015 - The European Generic and Biosimilar medicines Association (EGA) welcomes the new report from the IMS Institute for Healthcare Informatics on ‘The Role of Generic Medicines in Sustaining Healthcare Systems: A European Perspective’.
Launch of European Value Added medicines (EVA), a new EGA sector group, will deliver efficiency and better health outcomes for healthcare in Europe
Brussels, 12 June 2015 - The European Generic and Biosimilar medicines Association (EGA) announced today the launch of the European Value Added medicines (EVA) group, a new sector group of the EGA.
16 - 19 September 2015
27 January 2016
EGA Vision 2015, the Way forward for more Efficient Regulatory Environment for Generic and Biosimilar Medicines
GfK Final Report- Factors Supporting a Sustainable European Biosimilar Medicines Market
GfK Final Report - Factors Supporting a Sustainable European Biosimilar Medicines Market GfK Final Report- Factors Supporting a Sustainable European Biosimilar Medicines Market
Biosimilars: The science of extrapolation
Martina Weise, Pekka Kurki, Elena Wolff-Holz, Marie-Christine Bielsky, and Christian K. Schneider, Biosimilars: The science of extrapolation, Blood, 20 November 2014, Volume 124, NUMBER 22 Biosimilars_the_science_of_extrapolation.pdf
(free download for non-industry stakeholders only)
EGA Biosimilars Handbook
EGA Biosimilars Handbook
English version EGA_BIOSIMILARS_handbook_en.pdf
German version EGA_Biosimilars_ProGen-Biosimilars-A5-RZ-web_ende.pdf
Italian version EGA_BIOSIMILARS_IT.pdf
Spanish version EGA_BIOSIMILARS_INT_Spain.pdf